| # | Title | Journal | Year | Citations |
|---|
| 1 | Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib | Journal of Clinical Pharmacology | 2010 | 76 |
| 2 | Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia | European Journal of Clinical Pharmacology | 2013 | 70 |
| 3 | Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology | European Journal of Cancer | 2014 | 66 |
| 4 | Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants | Journal of Clinical Pharmacology | 2011 | 61 |
| 5 | Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia | British Journal of Clinical Pharmacology | 2008 | 50 |
| 6 | Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib | British Journal of Cancer | 2013 | 49 |
| 7 | Dose‐ and Time‐Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus | Journal of Clinical Pharmacology | 2008 | 38 |
| 8 | Clinical Pharmacology of Deferasirox | Clinical Pharmacokinetics | 2014 | 33 |
| 9 | A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects | Clinical Pharmacokinetics | 2008 | 26 |
| 10 | Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia | Cancer Chemotherapy and Pharmacology | 2012 | 25 |
| 11 | Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol | Clinical Pharmacology in Drug Development | 2015 | 20 |
| 12 | Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia | British Journal of Clinical Pharmacology | 2011 | 19 |
| 13 | Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients | Clinical Therapeutics | 2009 | 18 |
| 14 | Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers | Cancer Chemotherapy and Pharmacology | 2013 | 12 |
| 15 | Correlation between Nasal Membrane Permeability and Nasal Absorption Rate | AAPS PharmSciTech | 2013 | 6 |
| 16 | Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing’s Disease Patients | Clinical Pharmacokinetics | 2018 | 3 |
| 17 | CYP3A5 but Not CYP2D6 Polymorphism Contributes Significantly to the Variability in Dextropropoxyphene Disposition | Journal of Clinical Pharmacology | 2010 | 2 |
| 18 | Development and validation of an LC–MS/MS method for the quantitative analysis of the adenosine A2a receptor antagonist NIR178 and its monohydroxy metabolite in human plasma: Application to clinical pharmacokinetics | Biomedical Chromatography | 2020 | 2 |
| 19 | Meta-analysis on the relationship between everolimus exposure and safety and efficacy. | Journal of Clinical Oncology | 2012 | 1 |
| 20 | Octreotide (Oct) Lar Reconstituted in a New Vehicle (Nv): Phase 1, Open-Label, Randomized, Bioequivalence Study Vs Oct Lar 30 Mg (Current Vehicle) | Annals of Oncology | 2014 | 0 |
| 21 | Assessment of gastric pH changes and food intake on ribociclib bioavailability: In silico and clinical evaluations | Annals of Oncology | 2017 | 0 |
